Long-term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) With Relapsed/Refractory (r/r) Follicular Lymphoma (FL) Treated With Tisagenlecleucel in the ELARA Trial

被引：0

作者：

Dreyling, M. ^{[1
]}

Dickinson, M. ^{[2
,3
]}

Martinez-Lopez, J. ^{[4
]}

Kolstad, A. ^{[5
]}

Butler, J. ^{[6
]}

Ghosh, M. ^{[7
]}

Popplewell, L. ^{[8
]}

Chavez, J. C. ^{[9
]}

Bachy, E. ^{[10
,11
]}

Kato, K. ^{[12
]}

Harigae, H. ^{[13
]}

Kersten, M. J. ^{[14
]}

Andreadis, C. ^{[15
]}

Riedell, P. A. ^{[16
]}

Ho, P. J. ^{[17
,18
]}

Perez-Simon, J. A. ^{[19
]}

Chen, A. I. ^{[20
]}

Nastoupil, L. J. ^{[21
]}

Tresckow, B. V. ^{[22
,23
,24
]}

Ferreri, Maria A. J. ^{[25
]}

Teshima, T. ^{[26
]}

Patten, P. E. ^{[27
,28
]}

McGuirk, J. P. ^{[29
]}

Petzer, A. ^{[30
]}

Offner, F. ^{[31
]}

Viardot, A. ^{[32
]}

Zinzani, P. L. ^{[33
,34
]}

Malladi, R. ^{[35
]}

Paule, I. ^{[36
]}

Zia, A. ^{[36
]}

Awasthi, R. ^{[37
]}

Han, X. ^{[38
]}

Germano, D. ^{[36
]}

O'Donovan, D. ^{[39
]}

Ramos, R. ^{[38
]}

Masood, A. ^{[38
]}

Thieblemont, C. ^{[40
]}

Fowler, N. ^{[41
,42
]}

Schuster, S. J. ^{[43
]}

机构：

[1] LMU Klinikum, Med Klin 3, Munich, Germany

[2] Univ Melbourne, Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[3] Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[4] Univ Complutense, Hosp 12 Octubre, Madrid, Spain

[5] Oslo Univ Hosp, Oslo, Norway

[6] Royal Brisbane Hosp, Herston, Qld, Australia

[7] Univ Michigan, Michigan Med, Ann Arbor, MI 48109 USA

[8] City Hope Comprehens Canc Ctr, Duarte, CA USA

[9] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematologyy, Tampa, FL USA

[10] Hosp Civils Lyon, Lyon, France

[11] Univ Claude Bernard Lyon 1, Lyon, France

[12] Kyushu Univ Hosp, Dept Hematol Oncol & Cardiovasc Med, Fukuoka, Fukuoka, Japan

[13] Tohoku Univ Hosp, Sendai, Miyagi, Japan

[14] Univ Amsterdam, Dept Hematol, Ctr Canc, Amsterdam UMC, Amsterdam, Netherlands

[15] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[16] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[17] Royal Prince Alfred Hosp, Camperdown, NSW, Australia

[18] Univ Sydney, Camperdown, NSW, Australia

[19] Univ Seville, Inst Biomed Sevilla, Univ Hosp Virgen Rocio, Dept Hematol, Seville, Spain

[20] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

[21] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

[22] Univ Cologne, Med Fac, Dept Internal Med 1, Cologne, Germany

[23] Univ Cologne, Dept Internal Med 1, Univ Hosp Cologne, Cologne, Germany

[24] Univ Duisburg Essen, Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, West German Canc Ctr, Essen, Germany

[25] IRCCS San Raffaele Sci Inst, Lymphoma Unit, Milan, Italy

[26] Hokkaido Univ Hosp, Dept Hematol, Sapporo, Hokkaido, Japan

[27] Kings Coll London, Ctr Comprehens Canc, London, England

[28] Kings Coll Hosp London, Dept Haematol, London, England

[29] Univ Kansas Hosp & Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Westwood, KS USA

[30] Ordensklinikum Linz, Internal Med Hematol Stem Cell Transplantat 1, Hemostaseol & Med Oncol, Barmherzige Schwestern Elisabethinen, Linz, Austria

[31] UZ Gent, Ghent, Belgium

[32] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany

[33] IRCCS Azienda Ospedaliero Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

[34] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimenta, Bologna, Italy

[35] Cambridge Univ Hosp NHS Fdn Trust, Basel, Switzerland

[36] Novartis Pharma AG, Basel, Switzerland

[37] Novartis Inst BioMed Res, E Hanover, NJ USA

[38] Novartis Pharmaceut, E Hanover, NJ USA

[39] Novartis Pharmaceut, Dublin, Ireland

[40] Hop St Louis, Paris, France

[41] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[42] BostonGene, Waltham, MA USA

[43] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1085

引用

页码：306 / 308

页数：3

共 50 条

[31] Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Morschhauser, Franck
Carlo-Stella, Carmelo
Dickinson, Michael
Phillips, Tycel
Houot, Roch
Offner, Fritz
Haioun, Corinne
Corradini, Paolo
Hutchings, Martin
Sureda, Anna
Martinez-Lopez, Joaquin
Wrobel, Tomasz
Wu, Shang-Ju
Lundberg, Linda
Mulvihill, Estefania
Perez-Callejo, David
Relf, James
Panchal, Anesh
Humphrey, Kathryn
Bachy, Emmanuel
BLOOD, 2021, 138
[32] Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
Falchi, Lorenzo
Leppa, Sirpa
Wahlin, Bjorn E.
Nijland, Marcel
Christensen, Jacob Haaber
De Vos, Sven
Holte, Harald
Linton, Kim M.
Abbas, Aqeel
Wang, Liwei
Dinh, Minh
Elliott, Brian
Belada, David
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[33] CURRENT EPCORITAMAB PLUS RITUXIMAB AND LENALIDOMIDE (R2) PERCEPTIONS FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Levine, E.
Gentile, D.
Swain, R.
Bone, R. N.
Jennings-Zhang, L.
Jeune-Smith, Y.
Feinberg, B.
VALUE IN HEALTH, 2024, 27 (12) : S342 - S342
[34] Efficacy controls and long-term follow-up of patients (pts) treated with rituximab for relapsed or refractory, low-grade or follicular (R-LG/F) NHL.
McLaughlin, P
Grillo-López, AJ
Maloney, DG
Link, BK
Levy, R
Czuczman, MS
Cabanillas, F
Dallaire, BK
White, CA
BLOOD, 1998, 92 (10) : 414A - 415A
[35] Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
Jaeger, Ulrich
Tam, Constantine S.
Borchmann, Peter
McGuirk, Joseph P.
Johansen, Marianne
Waller, Edmund K.
Jaglowski, Samantha
Andreadis, Charalambos
Foley, Stephen R.
Westin, Jason R.
Fleury, Isabelle
Ho, P. Joy
Mielke, Stephan
Teshima, Takanori
Salles, Gilles
Schuster, Stephen J.
He, Fiona
Maziarz, Richard T.
Mayer, Sebastian
Makita, Shinichi
Kersten, Marie J.
Ghosh, Monalisa
Wagner-Johnston, Nina
Kato, Koji
Corradini, Paolo
Goto, Hideki
Colicino, Silvia
Agarwal, Abhijit
Lobetti-Bodoni, Chiara
Bishop, Michael R.
BLOOD ADVANCES, 2022, 6 (16) : 4816 - 4820
[36] Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib plus Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial
Trotman, Judith
Zinzani, Pier Luigi
Song, Yuqin
Delarue, Richard
Barnes, Gisoo
Kim, Pil
Ivanova, Elena
Tang, Boxiong
Mayer, Jiri
De Oliveira, Ana C.
Assouline, Sarit
Flowers, Christopher R.
BLOOD, 2023, 142
[37] Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial.
Zinzani, Pier Luigi
Mayer, Jiri
Auer, Rebecca
Bijou, Fontanet
De Oliveira, Ana C.
Flowers, Christopher
Merli, Michele
Bouabdallah, Krimo
Ganly, Peter S.
Johnson, Roderick
Yuen, Sam
Kingsley, Ed
Tumyan, Gayane
Assouline, Sarit E.
Ivanova, Elena
Pil, Kim
Huang, Jane
Delarue, Richard
Trotman, Judith
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[38] Subcutaneous Epcoritamab With Rituximab plus Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
Falchi, Lorenzo
Leppa, Sirpa
Wahlin, Bjorn E.
Nijland, Marcel
Christensen, Jacob Haaber
De Vos, Sven
Holte, Harald
Linton, Kim M.
Abbas, Aqeel
Wang, Liwei
Dinh, Minh
Elliott, Brian
Belada, David
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S392 - S392
[39] Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)
Kongtim, Piyanuch
Percival, Mary-Elizabeth M.
Martins, Timothy J.
Qin, Guangrong
Curley, Niall
Gardner, Kelda M.
Chien, Sylvia
Dai, Jin
Oehler, Vivian G.
Blau, C. Anthony
Hendrie, Paul C.
Cassaday, Ryan D.
Halpern, Anna B.
Scott, Bart L.
Walter, Roland B.
Smith, Heather
Marcucci, Guido
Becker, Pamela S.
BLOOD, 2022, 140 : 1200 - 1202
[40] Tazemetostat in Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Propensity Score-Matched Analysis of E7438-G000-101 Trial Outcomes
Proudman, David
Gupta, Deepshekhar
Nellesen, Dave
Wong, Alex
Yang, Jay
Kamp, Beth
Mamlouk, Khalid
Cheson, Bruce
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S403 - S403

← 1 2 3 4 5 →